# LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

Study · id `cardio:ct-nct05983250` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05983250](<https://clinicaltrials.gov/study/NCT05983250>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05983250

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease; Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 230 participants.

## Technical summary

Registry record NCT05983250. Randomized; quadruple masking; primary purpose treatment. Start 2024-01-10 (actual); primary completion 2026-06-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 230 participants (planned count; ClinicalTrials.gov record NCT05983250, source copy `cardio:ctgov-nct05983250-2026-07-24`, retrieved 2026-10-26)
- Started: 2024-01-10 (actual) (ClinicalTrials.gov record NCT05983250, source copy `cardio:ctgov-nct05983250-2026-07-24`, retrieved 2026-10-26)
- Primary completion: 2026-06-30 (actual) (ClinicalTrials.gov record NCT05983250, source copy `cardio:ctgov-nct05983250-2026-07-24`, retrieved 2026-10-26)
- Completion: 2028-10-30 (anticipated) (ClinicalTrials.gov record NCT05983250, source copy `cardio:ctgov-nct05983250-2026-07-24`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT05983250, source copy `cardio:ctgov-nct05983250-2026-07-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05983250-2026-07-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
- Acronym: LEVEL
- Condition: Pulmonary Hypertension
- Intervention (Drug): TNX-103
- Intervention (Drug): Placebo
- Lead sponsor: Tenax Therapeutics, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Medpace, Inc.
- Collaborator class: INDUSTRY
- Collaborator: Northwestern University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Tenax Therapeutics, Inc. (`cardio:org-tenax-therapeutics-inc`)
- Registry lists this organization as a collaborator: Medpace, Inc. (`cardio:org-medpace-inc`)
- Registry lists this organization as a collaborator: Northwestern University (`cardio:org-northwestern-university`)

## Provenance

Content hash: 3f7592b9fe1eedba1827b87c4c3d7d9fcd6abfa0896135c68868d3523681d777
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
